STOCK TITAN

Neurocrine (NBIX) legal chief exercises options and sells 10,000 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Neurocrine Biosciences Chief Legal Officer Darin Lippoldt exercised stock options for 10,000 shares of common stock and sold 10,000 shares in open-market transactions. The options had an exercise price of $81.49 per share, while the reported sales occurred around $169.57–$170.91 per share on June 26 and June 29, 2026.

The filing shows this as an exercise-and-sell pattern, converting option value into cash rather than increasing net share ownership. After these transactions, Lippoldt directly holds 54,729 shares of Neurocrine Biosciences common stock and retains additional non-qualified stock options. The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 9, 2025.

Positive

  • None.

Negative

  • None.
Insider Lippoldt Darin
Role Chief Legal Officer
Sold 10,000 shs ($1.70M)
Type Security Shares Price Value
Exercise Non-Qualified Stock Option 8,110 $0.00 --
Exercise Non-Qualified Stock Option 1,690 $0.00 --
Exercise Common Stock 8,110 $81.49 $661K
Sale Common Stock 8,110 $170.025 $1.38M
Exercise Common Stock 1,690 $81.49 $138K
Sale Common Stock 1,690 $170.8144 $289K
Exercise Non-Qualified Stock Option 200 $0.00 --
Exercise Common Stock 200 $81.49 $16K
Sale Common Stock 200 $169.565 $34K
Holdings After Transaction: Non-Qualified Stock Option — 16,655 shares (Direct, null); Common Stock — 62,839 shares (Direct, null)
Footnotes (1)
  1. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $169.56 to $169.57. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $169.57 to $170.56. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $170.58 to $170.91. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The option was granted February 5, 2018 and vested in 48 equal monthly installments beginning March 5, 2018.
Shares sold 10,000 shares Total NBIX common shares sold in open-market transactions on June 26 and June 29, 2026
Option exercise price $81.49 per share Exercise price of non-qualified stock options converted into common stock
Sale price example $170.8144 per share Weighted average price for a 1,690-share sale of NBIX common stock
Post-transaction holdings 54,729 shares NBIX common shares directly owned by Lippoldt after reported transactions
Option expiration February 5, 2028 Expiration date for reported non-qualified stock options after partial exercise
Option exercises 10,000 shares Total common shares acquired through option exercises in this filing
Rule 10b5-1 trading plan regulatory
"The disposition reported ... was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted..."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Non-Qualified Stock Option financial
"security_title: "Non-Qualified Stock Option" with underlying security title "Common Stock""
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
weighted average sales price per share financial
"Represents a weighted average sales price per share. These shares were sold in multiple transactions..."
vested in 48 equal monthly installments financial
"The option was granted February 5, 2018 and vested in 48 equal monthly installments beginning March 5, 2018."
open-market sale financial
"transaction_action: "open-market sale" for common stock dispositions coded "S""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

How many Neurocrine Biosciences (NBIX) shares did Darin Lippoldt sell?

He sold a total of 10,000 NBIX common shares in several open-market trades on June 26 and June 29, 2026. The reported weighted average sale prices ranged from about $169.56 to $170.91 per share across multiple transactions.

What prices were reported for Darin Lippoldt’s NBIX share sales?

The filing shows weighted average sale prices near $169.57, $170.03, and $170.81 per NBIX share. Detailed footnotes note multiple trades within tight ranges from $169.56 up to $170.91, available on request from the issuer or SEC staff.

How many NBIX shares does Darin Lippoldt hold after these transactions?

Following the June 2026 transactions, Darin Lippoldt directly holds 54,729 shares of Neurocrine Biosciences common stock. The Form 4 also indicates he continues to hold non-qualified stock options with remaining balances after the reported exercises.

Were Darin Lippoldt’s NBIX stock sales made under a Rule 10b5-1 plan?

Yes. A footnote explains the dispositions were executed by a broker under a Rule 10b5-1 trading plan adopted on June 9, 2025. The company’s policy restricts him from amending or modifying such a plan after adoption.

What were the terms of the NBIX stock options Darin Lippoldt exercised?

The exercised non-qualified stock options had a conversion or exercise price of $81.49 per share and were originally granted on February 5, 2018. A footnote states they vested in 48 equal monthly installments beginning March 5, 2018.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lippoldt Darin

(Last)(First)(Middle)
6027 EDGEWOOD BEND CT.

(Street)
SAN DIEGO CALIFORNIA 92130

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Legal Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/26/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/26/2026M200A$81.4954,929D
Common Stock06/26/2026S(1)200D$169.565(2)54,729D
Common Stock06/29/2026M8,110A$81.4962,839D
Common Stock06/29/2026S(1)8,110D$170.025(3)54,729D
Common Stock06/29/2026M1,690A$81.4956,419D
Common Stock06/29/2026S(1)1,690D$170.8144(4)54,729D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Non-Qualified Stock Option$81.4906/26/2026M200 (5)02/05/2028Common Stock200$024,765D
Non-Qualified Stock Option$81.4906/29/2026M8,110 (5)02/05/2028Common Stock8,110$016,655D
Non-Qualified Stock Option$81.4906/29/2026M1,690 (5)02/05/2028Common Stock1,690$014,965D
Explanation of Responses:
1. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
2. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $169.56 to $169.57. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
3. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $169.57 to $170.56. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
4. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $170.58 to $170.91. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
5. The option was granted February 5, 2018 and vested in 48 equal monthly installments beginning March 5, 2018.
Remarks:
/s/ Darin Lippoldt06/30/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)